A study, published in Cancer Epidemiology, Biomarkers & Prevention, found that risk models that include established clinical, genetic, and circulating factors were able to better identify people at significantly higher than normal risk of pancreatic cancer over those using clinical factors alone.1
However, further refinement and validation of these models in independent samples is still necessary in order to make the models clinically actionable and impact survival of patients with pancreatic cancer according to the researchers.
“Pancreatic cancer is a particularly deadly cancer, with about 80 percent of patients diagnosed with advanced, incurable disease,” lead author Peter Kraft, PhD, professor of epidemiology at the Harvard T.H. Chan School of Public Health in Boston, said in a press release.2 “Catching it at an earlier stage makes it more likely that surgery will be an…
